Silexion Therapeutics Announces 1-for-10 Reverse Stock Split Effective May 29 to Maintain Nasdaq Listing
SLXN sits 78% above its 52-week low of $0.231.
Summary
Silexion Therapeutics announced a 1-for-10 reverse stock split, effective May 29, 2026, primarily to meet Nasdaq's minimum bid price requirement and facilitate future financing efforts.
Key Events · Corporate Governance and Compliance · SLXN
-
Reverse Stock Split Effective
A 1-for-10 reverse share split will become effective after market close on May 28, 2026, with trading on a split-adjusted basis beginning May 29, 2026.
-
Nasdaq Compliance
The primary purpose of the reverse split is to enable the company to maintain compliance with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)).
-
Enables Future Financing
The company expects a higher per-share trading range to reduce volatility, broaden the investor base, and improve flexibility to fund the advancement of its lead product candidate, SIL204.
-
Follows Shareholder Approval
This action follows shareholder approval received on May 5, 2026, for the reverse stock split and an increase in authorized shares, after an initial rejection of similar proposals in March.
Analysis · SLXN · Life Sciences
Silexion Therapeutics is implementing a 1-for-10 reverse stock split, effective May 29, 2026. This action is critical for the company to regain compliance with Nasdaq's minimum bid price requirement, a necessary step given its recent 'going concern' warnings and stated need for future dilutive financing. Without this split, the company faced a high risk of delisting, which would severely impede its ability to raise capital and continue operations, particularly as it approaches a Phase 2/3 clinical trial for SIL204.
At the time of this filing, SLXN was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $0.23 to $22.36. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.